Compare
Northwest Biotherapeutics Inc vs Cannapharmarx, Inc. vs Avenue Therapeutics, Inc. vs NRX Pharmaceuticals, Inc.
| Latest fiscal year | Northwest Biotherapeutics Inc NWBO | Cannapharmarx, Inc. CPMD | Avenue Therapeutics, Inc. ATXI | NRX Pharmaceuticals, Inc. NRXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.38M | $1.36M | $1.40M | $1.45M |
| Revenue growth (YoY) | -0.3% | +66.1% | n/a | n/a |
| Gross margin | n/a | -153.1% | n/a | 65.1% (computed) |
| Operating margin | n/m | -245.8% | -219.6% | n/m |
| Net margin | n/m | -817.2% | -207.2% | n/m |
| Net income | -$60.16M | -$11.13M | -$2.91M | -$28.62M |
| EPS (Diluted) | -$0.04 | -$0.02 | n/a | n/a |
| Operating cash flow | -$44.76M | -$789.1K | -$1.83M | -$14.11M |
| Free cash flow | -$46.27M | -$794.6K | n/a | n/a |
| Cash & equivalents | $3.04M | $1.8K | $2.85M | $7.80M |
| Total assets | $81.29M | $7.02M | $2.93M | $12.96M |
| Total liabilities | $128.86M | $37.17M | $1.10M | $28.89M |
| Shareholders' equity | -$60.28M | -$30.15M | $1.83M | -$15.94M |
| Return on year-end equity | n/a | n/a | -158.8% | n/a |
| Shares outstanding | 1.56B | 662.50M | 3.18M | 31.73M |
Revenue, most recent five fiscal years
| Fiscal year | Northwest Biotherapeutics Inc | Cannapharmarx, Inc. | Avenue Therapeutics, Inc. | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $1.38M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $1.40M Ended 2025-12-31 | $1.45M Ended 2025-12-31 |
| 1 year earlier | $1.38M Ended 2024-12-31 | $820.1K Ended 2024-12-31 | $0 Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | $1.68M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $1.00M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a | n/a |